[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) Form 144 notice records a proposed sale of 36,796 Class A shares with an aggregate market value of $356,921, intended for sale on 08/22/2025 on NASDAQ. The filer reports the shares were acquired as equity compensation from Amneal Pharmaceuticals on 03/01/2023 (18,628 shares) and 03/03/2023 (18,168 shares). The filing also discloses three recent sales by the same person during August 2025 totaling 205,730 Class A shares for gross proceeds of $1,935, - [aggregate per rows: $818,930; $663,065; $453,000]. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and warning about false statements.

Positive

• Form 144 filed in compliance with Rule 144 disclosure requirements, providing transparency about proposed insider sales
• Securities acquired via equity compensation are clearly identified with acquisition dates and amounts

Negative

• Insider reported multiple recent sales in August 2025 totaling 205,730 Class A shares, which may indicate meaningful insider liquidity
• Proposed sale of 36,796 shares scheduled for 08/22/2025 adds to recent dispositions by the same person

Insights

Securities Analyst

TL;DR: Insider filed a Form 144 for ~36.8k shares and reported recent August sales totaling 205.7k shares.

The filing documents a routine Rule 144 notice: the securities to be sold were acquired via equity compensation in March 2023 and the proposed sale is scheduled for 08/22/2025 on NASDAQ. The same person reported three prior sales in August 2025 totaling 205,730 shares with gross proceeds listed by sale. This is a disclosure of intent to sell and prior dispositions rather than an operational disclosure about the company; it provides transparency on insider liquidity but does not, by itself, disclose company performance or material nonpublic information.

Corporate Governance Expert

TL;DR: Filing complies with Rule 144 mechanics and includes standard seller representations.

The notice identifies the nature of acquisition as equity compensation and lists the broker and execution venue. It includes required seller attestations regarding material nonpublic information and a signature warning about false statements, indicating procedural compliance. From a governance perspective, this documents an insider exercising liquidity rights under Rule 144; without additional context on timing or volume relative to insider holdings, the filing is a routine disclosure rather than a governance red flag.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
CLASS A	MERRILL LYNCH 157 CHURCH ST, FL 26 NEW HAVEN CT 06510	36796	356921.00	314079309	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
CLASS A	03/01/2023	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			18628	03/01/2023	EQUITY COMPENSATION
CLASS A	03/03/2023	EQUITY COMPENSATION	AMNEAL PHARMACEUTICALS			18168	03/03/2023	EQUITY COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
NIKITA SHAH 400 CROSSING BLVD BRIDGEWATER NJ 08807	CLASS A	08/22/2025	84036	818930.00
NIKITA SHAH 400 CROSSING BLVD BRIDGEWATER NJ 08807	CLASS A	08/14/2025	71694	663065.00
NIKITA SHAH 400 CROSSING BLVD BRIDGEWATER NJ 08807	CLASS A	08/12/2025	50000	453000.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Amneal Pharmaceuticals (AMRX) Form 144 disclose about proposed sales?

The notice discloses a proposed sale of 36,796 Class A shares (aggregate market value $356,921) intended to be sold on 08/22/2025 on NASDAQ.

How were the shares being sold by the filer acquired?

The filer acquired the reported shares as equity compensation from Amneal Pharmaceuticals on 03/01/2023 (18,628 shares) and 03/03/2023 (18,168 shares).

Did the filer sell other Amneal (AMRX) shares recently?

Yes. The same person reported three sales in August 2025: 84,036 shares for $818,930, 71,694 shares for $663,065, and 50,000 shares for $453,000.

On which exchange and through which broker is the proposed sale to occur?

The proposed sale is listed to occur on NASDAQ through broker Merrill Lynch at the address shown.

Does the Form 144 include a representation about material nonpublic information?

Yes. The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.